Shopping Cart
Remove All
Your shopping cart is currently empty
HDAC-IN-27
Catalog No. T61209 Copy Product Info
Purity: 99.13%
🥰Excellent
HDAC-IN-27 is a highly potent and orally bioavailable class I HDAC-selective inhibitor with IC₅₀ values ranging from 0.43 to 3.01 nM against HDAC1–3. It shows significant anti-tumor activity in vitro and in vivo, exerts prominent anti-proliferative effects on acute myeloid leukemia (AML) cell lines, and achieves its biological effects by inducing apoptosis and promoting acetylation of histones H3 and H4 (AcHH3, AcHH4), making it applicable in acute myeloid leukemia research.
HDAC-IN-27
Copy Product Info🥰Excellent
Catalog No. T61209
HDAC-IN-27 is a highly potent and orally bioavailable class I HDAC-selective inhibitor with IC₅₀ values ranging from 0.43 to 3.01 nM against HDAC1–3. It shows significant anti-tumor activity in vitro and in vivo, exerts prominent anti-proliferative effects on acute myeloid leukemia (AML) cell lines, and achieves its biological effects by inducing apoptosis and promoting acetylation of histones H3 and H4 (AcHH3, AcHH4), making it applicable in acute myeloid leukemia research.
Cas No. 2763368-89-2
| Pack Size | Price | USA Stock | Global Stock | Quantity |
|---|---|---|---|---|
| 1 mg | $47 | - | In Stock | |
| 5 mg | $108 | - | In Stock | |
| 10 mg | $176 | - | In Stock | |
| 25 mg | $355 | - | In Stock | |
| 50 mg | $568 | - | In Stock | |
| 100 mg | $892 | - | In Stock |
For In stock only · Estimated delivery: USA Stock (1-2 days) Global Stock (5-7 days)
Add to Cart
Add to Quotation
With extensive experience in compound synthesis, we can provide rapid custom synthesis services for this product according to your research needs.
For research use only—not for human use. No sales to individuals. Use as intended only.
Batch Information
Select Batch
Purity:99.13%
Appearance:Solid
Color:White
Contact us for more batch information
Product Introduction
Bioactivity
Chemical Properties
Storage & Solubility Information
| Description | HDAC-IN-27 is a highly potent and orally bioavailable class I HDAC-selective inhibitor with IC₅₀ values ranging from 0.43 to 3.01 nM against HDAC1–3. It shows significant anti-tumor activity in vitro and in vivo, exerts prominent anti-proliferative effects on acute myeloid leukemia (AML) cell lines, and achieves its biological effects by inducing apoptosis and promoting acetylation of histones H3 and H4 (AcHH3, AcHH4), making it applicable in acute myeloid leukemia research. |
| Targets&IC50 | HDAC1:3.01 nM, HDAC2:18.54 nM, HDAC3:0.435 nM |
| In vitro | Methods: MV4-11 cells and HL60 cells with wild-type p53 were treated with HDAC-IN-27 for 11 hours, and caspase-3 cleavage, cell apoptosis, sub-G1 phase ratio and cell cycle distribution were detected. Results: 1 In MV4-11 cells with wild-type p53, HDAC-IN-27 could induce pro-caspase-3 cleavage, significant apoptotic cell death and accumulation of cells in the sub-G1 phase. 2 In HL60 cells, HDAC-IN-27 mainly induced G2/M phase arrest, and no obvious apoptotic phenomenon was observed [1]. |
| Molecular Weight | 350.41 |
| Formula | C20H22N4O2 |
| Cas No. | 2763368-89-2 |
| Smiles | O=C(NNCCC)C1=CC=C(C=C1)CNC(=O)C2=CC=3C=CC=CC3N2 |
| Storage | Powder: -20°C for 3 years | In solvent: -80°C for 1 year Shipping with blue ice/Shipping at ambient temperature. | |||||||||||||||||||||||||
| Solubility Information | DMSO: 13.34 mg/mL (38.07 mM), Sonication is recommended. | |||||||||||||||||||||||||
Solution Preparation Table | ||||||||||||||||||||||||||
DMSO
Note : The dilution table applies only to solid products. For liquid products, please calculate the stock solution based on the stated concentration and/or density. | ||||||||||||||||||||||||||
Citations
Calculator
In Vivo Formulation Calculator (Clear solution)
Please enter your animal experiment information in the following box and click Calculate to obtain the stock solution preparation method and in vivo formula preparation method:
For example, if the intended dosage is 10 mg/kg for animals weighing 20 g , with a dosing volume of 100 μL per animal, and a total of 10 animals are to be administered, using a formulation of 
10% DMSO+ 40% PEG300+ 5% Tween 80+ 45% Saline/PBS/ddH2O , the resulting working solution concentration would be 2 mg/mL.Stock Solution Preparation:
Dissolve 2 mg of the compound in 100 μL DMSO to obtain a stock solution at a concentration of 20 mg/mL . If the required concentration exceeds the compound's known solubility, please contact us for technical support before proceeding.
Preparation of the In Vivo Formulation:
1) Add 100 μL of the DMSO stock solution to 400 μL PEG300 and mix thoroughly until the solution becomes clear.
2) Add 50 μL Tween 80 and mix well until fully clarified.
3) Add 450 μL Saline,PBS or ddH2O and mix thoroughly until a homogeneous solution is obtained.
This example is provided solely to demonstrate the use of the In Vivo Formulation Calculator and does not constitute a recommended formulation for any specific compound. Please select an appropriate dissolution and formulation strategy based on your experimental model and route of administration.
Dose Conversion
You can also refer to dose conversion for different animals. More Dose Conversion
Tech Support
Please see Inhibitor Handling Instructions for more frequently ask questions. Topics include: how to prepare stock solutions, how to store products, and cautions on cell-based assays & animal experiments, etc
Preview
Related Tags: buy HDAC-IN-27 | purchase HDAC-IN-27 | HDAC-IN-27 cost | order HDAC-IN-27 | HDAC-IN-27 chemical structure | HDAC-IN-27 in vitro | HDAC-IN-27 formula | HDAC-IN-27 molecular weight
Generate Quote
Catalog No.: Cas No.:
Add
| Size | Quantity | Unit Price | Amount | Operation |
|---|
Generate Quote
- TOP
Feedback
Hello! How can I help you today? 
Copyright © 2015-2026 TargetMol Chemicals Inc. All Rights Reserved.